The US Food and Drug Administration (FDA) has awarded the second breakthrough therapy designation (BTD) to Johnson & ...

Spring House, Massachusetts Wednesday, November 13, 2024, 14:00 Hrs [IST] ...

UK’s “Ensuring Economic Growth” report underscores the use of distributed ledger technology (DLT), particularly through the ...

With BTD, Vaxcyte will have access to all the elements of the FDA’s Fast Track program, as well as the ability to receive guidance and support from the FDA on an efficient drug development program and ...

Johnson & Johnson (J&J) has announced that its anti-FcRn antibody nipocalimab has become the first investigational therapy to ...

Vaxcyte (PCVX) announced positive regulatory updates, including the United States Food and Drug Administration, FDA, clearance of the VAX-31 ...

Johnson & Johnson announced that the U.S. Food and Drug Administration has granted nipocalimab Breakthrough Therapy designation for the ...

Setrusumab (UX143) recently received the FDA's Breakthrough Therapy Designation (BTD) for osteogenesis imperfect following ...

Click here for a full investment analysis of Cybin Inc., a speculative play on FDA approval for psychedelic-based treatments.

Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication: ...

Commander Noel Johnson, Chief of the Platform Division in the Office of Boat Forces, opened the International WorkBoat Show’s ...